Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statementsThis news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding financial performance, timing of clinical trials and data, relevance of GW products commercially available and in development, size of market opportunities, and development and regulatory clearance of GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. GW Pharmaceuticals plc

Consolidated income statement

For the year ended 30 September 2013Year endedYear endedYear ended30 Septemb
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... ... Displays and Exhibits , a top online retailer of trade show ... include branding. Enter price code brand2015 for a ten percent discount on all branded ... materials, all should integrate the company logo to communicate the brand. What is communicated ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... , **FDAnews Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... application of human factors engineering to the design of new products as well ...
(Date:6/29/2015)... ... 2015 , ... People across the country give their coworkers and families gifts all the time. ... , But, how often do coworkers donate “life” to the husband of a coworker? For ... , “Dawna (Wright-Thompson) told me her husband was on a donor list,” Glenshaw resident Kathi ...
(Date:6/29/2015)... York, New York (PRWEB) , ... June 29, ... ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against C.R. Bard, Inc. and Ethicon, ... to court documents, the proceedings’ next Case Management Conference is to be convened ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
... , WASHINGTON, Sept. 16 Speaker Nancy ... Senator Max Baucus, Chairman of the Senate Finance Committee: , ... all Americans and requiring accountability for insurance companies are two of ... "We look forward to studying the impact of the Senate Finance ...
... ... harvest 2009-2010. ,Complete version available at http://www.pinenutoil.org/pine-nut-oil/wholesale-prices.php , ... New York, New York (PRWEB) September 16, 2009 -- In ... harvest 2009 - 2010 . , , , , ,The attention was drawn to one ...
... , , , ... , WASHINGTON , Sept. 16 This ... host a Congressional townhall panel that will discuss the economic and moral ... the fourth annual Values Voter Summit and will feature Congressman ...
... , WASHINGTON, Sept. 16 We commend the ... an equitable and affordable approach to making health care coverage accessible ... , , We especially appreciate the committee,s preservation ... and home health market basket update for 2010 remains whole). We ...
... , ABBOTT PARK, Ill., Sept. ... the company,s schedule of key news announcements and events during ... Sept. 21 - 25. Highlights include the presentation of new ... Coronary Stent System. One-year results from the SPIRIT IV trial, ...
... , , , UNION ... a medical products company manufacturing point-of-care blood analysis systems, announced today that ... Global Life Sciences Conference on Wednesday, September 23, 2009 at 12:00 p.m. ... Hotel in New York City. , , About ...
Cached Medicine News:Health News:Pine Nut Oil.org Presents Best Price for Pine Nut Oil 2Health News:Pine Nut Oil.org Presents Best Price for Pine Nut Oil 3Health News:Pine Nut Oil.org Presents Best Price for Pine Nut Oil 4Health News:Pine Nut Oil.org Presents Best Price for Pine Nut Oil 5Health News:Townhall Comes to Washington: FRC Action to Host Congressional Forum on Health Care 2Health News:AAHSA Statement on Senate Finance Committee's Health Reform Bill 2Health News:Abbott Announces TCT 2009 Activities 2Health News:Abbott Announces TCT 2009 Activities 3Health News:Abbott Announces TCT 2009 Activities 4Health News:Abbott Announces TCT 2009 Activities 5
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: